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Dear Editor,
The identification of target combinationswith synergistic effects
on cancer is at the leading edge of modern cancer research,
especially for thedevelopment of combinedanticancer therapies.1
However, at present, the basis for selection of beneficial target
combinations commonly relies on expert opinion without any
systematic rationale. The development of high-throughput tech-
nologies has led to the availability of large-scale clinical gene
expression data sets.2–4Mining of these data sets for identification
of gene combinations with synergetic effects on survival outcome
in cancer could provide a systematic rationale for the identification
of target combinations with potential therapeutic synergy.
Multiple online tools have been developed recently to assess
the relationship between expression of a single gene and clinical
outcome across a variety of cancers.5,6 Here we present
SynTarget, the first tool able to test the cumulative effect of two
genes on survival outcomeand, therefore, can identify gene pairs
with synergistic effects. At present, SynTarget is based on 15
large-scale gene expression data sets covering eight different
cancers with the possibility to select clinically important subtypes
(i.e., triple-negative, p53 mutated cancers, K-ras mutated
cancers etc.). On submission, the user selects a specific cancer
data set and subtype and specifies two genes. Patients in the
selected data set (subtype) are split into four groups with respect
to the expression of the specified genes (high−high, high− low,
low−high and low− low). Next, each group is tested versusother
samples to find any statistical differences in survival outcome
(i.e., high−high versus others, high− low versus others and so
on). This information is accompanied by individual-gene survival
effects in order to understand the degree of gene synergy.
Among other drug classes, immunotherapeutic agents have
enormous potential for synergistic combinations.1 Triple-
negative breast cancer is the subtype with the worst prognosis
among all breast cancer subtypes, with currently no known
molecular targets.7 We used SynTarget to search cell surface
genes with the synergistic potential on survival, whose high
expression leads to significantly negative prognosis. For
example, ADAM9 is a membrane-anchored protein and has
been implicated in a variety of biological processes, as well as
being involved in cancer metastasis. RC3H2 is a membrane-
associated nucleic acid-binding protein. High expression of
both genes individually was slightly negatively associated
(P-values ~ 0.07 and 0.04) with survival in triple-negative
patients from theMETABRIC data set.3 The subgroup of triple-
negative patients where both genes are highly expressed has
a significantly negative shift (P-valueo6e−05) in survival, in
comparison with other patients (see Supplementary Materials
for details). Therefore, SynTarget provides statistical evidence
that high expression of both RC3H2 and ADAM9 synergistically
affects survival of patients with triple-negative breast cancer.
In summary, SynTarget supports the need of biomedical
researchers to estimate the synergy of gene expression on
survival of cancer patients. To our knowledge this is a first tool of
this kind and, as shown by several examples (see Supplementary
Materials), SynTarget can be used for fast validation of the clinical
synergy for two genes.SynTarget is incorporated into BioProfiling.
de, an analytical portal for high-throughput cell biology,8 and is
freely available at http://www.bioprofiling.de/synergy2G.
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